Valuation dashboard for Cerus Corporation (CERS) with P/E N/A, P/B 6.88, EV/EBITDA 192.78 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma.
Analysis Summary
Cerus Corporation reported revenue of $206.1M in the most recent fiscal year, growing at a 5-year CAGR of 17.5%.
Trailing-twelve-month margins: gross margin 52.0%, operating margin -0.7%, net margin -3.1%.
At the current price of $2.53, CERS has negative trailing earnings (P/E not meaningful) and an ROE of -10.31%. Market capitalisation stands at $510M.
Balance sheet quality for CERS: current ratio of 1.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 6.88 |
| EV / EBITDA | 192.78 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $2.67 |
| vs Current Price | +5.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CERS | Cerus Corporation | $510M | 6.88 | -10.3% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 29.27 | 4.55 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $66.5B | 48.91 | 5.86 | 11.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price
| Price | $2.53 |
| Market Cap | $510M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -10.31% |
| Return on Invested Capital | -1.06% |
| Return on Assets | -3.31% |
| Gross Margin | 52.05% |
| Operating Margin | -0.73% |
| Net Margin | -3.06% |
Related companies: CVRX · MASS · NPCE · QTRX · RXST · SENS · SGHT
Explore sector: Healthcare · Medical - Devices
More sections of CERS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks